Systemic administration of optimized aptamer-siRNA chimeras promotes regression of PSMA-expressing tumors.
Prostate cancer cells expressing prostate-specific membrane antigen (PSMA) have been targeted with RNA aptamer-small interfering (si)RNA chimeras, but therapeutic efficacy in vivo was demonstrated only with intratumoral injection. Clinical translation of this approach will require chimeras that are effective when administered systemically and are amenable to chemical synthesis. To these ends, we enhanced the silencing activity and specificity of aptamer-siRNA chimeras by incorporating modifications that enable more efficient processing of the siRNA by the cellular machinery. These included adding 2-nucleotide 3'-overhangs and optimizing the thermodynamic profile and structure of the duplex to favor processing of the siRNA guide strand. We also truncated the aptamer portion of the chimeras to facilitate large-scale chemical synthesis. The optimized chimeras resulted in pronounced regression of PSMA-expressing tumors in athymic mice after systemic administration. Anti-tumor activity was further enhanced by appending a polyethylene glycol moiety, which increased the chimeras' circulating half-life.
Dassie
Justin P
JP
Department of Internal Medicine, University of Iowa, Iowa City, Iowa, USA.
Liu
Xiu-Ying
XY
Thomas
Gregory S
GS
Whitaker
Ryan M
RM
Thiel
Kristina W
KW
Stockdale
Katie R
KR
Meyerholz
David K
DK
McCaffrey
Anton P
AP
McNamara
James O
JO
Giangrande
Paloma H
PH
D000818:Animals; D000954:Antigens, Surface / Q000097:blood*; D052157:Aptamers, Nucleotide / Q000008:administration & dosage* / Q000235:genetics; D018797:Cell Cycle Proteins / Q000378:metabolism; D048708:Cell Growth Processes / Q000235:genetics; D045744:Cell Line, Tumor; D002470:Cell Survival / Q000235:genetics; D043425:Glutamate Carboxypeptidase II / Q000097:blood*; D006801:Humans; D008297:Male; D051379:Mice; D008819:Mice, Nude; D009690:Nucleic Acid Conformation; D011471:Prostatic Neoplasms / Q000235:genetics* / Q000378:metabolism / Q000473:pathology / Q000628:therapy*; D017346:Protein Serine-Threonine Kinases / Q000378:metabolism; D011518:Proto-Oncogene Proteins / Q000378:metabolism; D034741:RNA, Small Interfering / Q000008:administration & dosage* / Q000235:genetics; D023041:Xenograft Model Antitumor Assays; D000097869:Polo-Like Kinase 1
D000954:Antigens, Surface; D052157:Aptamers, Nucleotide; D018797:Cell Cycle Proteins; D043425:Glutamate Carboxypeptidase II; D017346:Protein Serine-Threonine Kinases; D011518:Proto-Oncogene Proteins; D034741:RNA, Small Interfering; D000097869:Polo-Like Kinase 1; C473848:FOLH1 protein, human
Adv Drug Deliv Rev. 2007 Mar 30;59(2-3):75-86
17449137
Am J Clin Oncol. 2008 Oct;31(5):496-503
18838889
Nucleic Acids Res. 2005 Jul 26;33(13):4140-56
16049023
Cancer Res. 2008 Apr 1;68(7):2358-65
18381443
Nature. 2007 Dec 13;450(7172):1117-20
18075597
Nat Med. 2005 Sep;11(9):944-51
16116432
Circulation. 2006 Dec 5;114(23):2490-7
17101847
Nat Rev Drug Discov. 2007 Jun;6(6):443-53
17541417
Adv Drug Deliv Rev. 2007 Mar 30;59(2-3):134-40
17451840
Nat Rev Cancer. 2006 Apr;6(4):321-30
16557283
Circulation. 2007 Dec 4;116(23):2678-86
18025536
Nucleic Acids Res. 2008 Oct;36(18):5812-21
18782830
Nat Protoc. 2008;3(6):1077-84
18536652
Mol Vis. 2003 May 30;9:210-6
12789138
Mol Cancer Ther. 2006 Jul;5(7):1790-9
16891465
Oligonucleotides. 2005 Fall;15(3):183-95
16201906
Oligonucleotides. 2008 Dec;18(4):305-19
19025401
Nat Biotechnol. 2004 Mar;22(3):326-30
14758366
IUBMB Life. 2005 Oct;57(10):677-82
16223707
Mol Ther. 2009 Mar;17(3):538-47
19088704
Proc Natl Acad Sci U S A. 2007 Apr 3;104(14):5715-21
17379663
Nat Chem Biol. 2006 Dec;2(12):711-9
17108989
Nucleic Acids Res. 2003 Jun 1;31(11):2705-16
12771196
Can J Urol. 2008 Aug;15 Suppl 1:14-20; discussion 20
18700061
Cancer Res. 2005 Oct 1;65(19):8984-92
16204072
Nat Med. 2005 Jan;11(1):50-5
15619632
Int Ophthalmol Clin. 2006 Fall;46(4):141-54
17060800
Hum Gene Ther. 2008 Feb;19(2):111-24
18230025
Clin Exp Metastasis. 2005;22(8):674-84
16703413
Biochemistry. 2006 Jun 20;45(24):7639-43
16768459
BioDrugs. 2008;22(5):315-29
18778113
Nature. 2004 May 20;429(6989):318-322
15152257
Proc Natl Acad Sci U S A. 2007 Aug 7;104(32):12982-7
17652171
Nat Biotechnol. 2007 Oct;25(10):1149-57
17873866
Circulation. 2008 Jun 3;117(22):2865-74
18506005
Nat Biotechnol. 2005 Jun;23(6):709-17
15908939
Cell. 2003 Oct 17;115(2):209-16
14567918
Antiviral Res. 2008 Mar;77(3):225-31
18242722
Proc Natl Acad Sci U S A. 2007 Mar 6;104(10):4095-100
17360483
FASEB J. 2005 Apr;19(6):611-3
15661849
Mol Ther. 2006 Oct;14(4):476-84
16829204
Nature. 2007 Jul 5;448(7149):39-43
17572664
Cell. 2003 Oct 17;115(2):199-208
14567917
Mol Ther. 2008 Aug;16(8):1481-9
18461053
Hum Gene Ther. 2006 Oct;17(10):1019-26
17007568
Nat Biotechnol. 2006 Aug;24(8):1005-15
16823371
Cancer Res. 2002 Jul 15;62(14):4029-33
12124337